Linking uric acid metabolism to diabetic complications
- PMID: 25512781
- PMCID: PMC4265865
- DOI: 10.4239/wjd.v5.i6.787
Linking uric acid metabolism to diabetic complications
Abstract
Hyperuricemia have been thought to be caused by the ingestion of large amounts of purines, and prevention or treatment of hyperuricemia has intended to prevent gout. Xanthine dehydrogenase/xanthine oxidase (XDH/XO) is rate-limiting enzyme of uric acid generation, and allopurinol was developed as a uric acid (UA) generation inhibitor in the 1950s and has been routinely used for gout prevention since then. Serum UA levels are an important risk factor of disease progression for various diseases, including those related to lifestyle. Recently, other UA generation inhibitors such as febuxostat and topiroxostat were launched. The emergence of these novel medications has promoted new research in the field. Lifestyle-related diseases, such as metabolic syndrome or type 2 diabetes mellitus, often have a common pathological foundation. As such, hyperuricemia is often present among these patients. Many in vitro and animal studies have implicated inflammation and oxidative stress in UA metabolism and vascular injury because XDH/XO act as one of the major source of reactive oxygen species Many studies on UA levels and associated diseases implicate involvement of UA generation in disease onset and/or progression. Interventional studies for UA generation, not UA excretion revealed XDH/XO can be the therapeutic target for vascular injury and renal dysfunction. In this review, the relationship between UA metabolism and diabetic complications is highlighted.
Keywords: Diabetes mellitus; Diabetic complications; Metabolism; Uric acid; Xanthine dehydrogenase/xanthine oxidase; Xanthine oxidase inhibitor.
Similar articles
-
Xanthine Oxidoreductase Inhibitors.Handb Exp Pharmacol. 2021;264:205-228. doi: 10.1007/164_2020_383. Handb Exp Pharmacol. 2021. PMID: 32789757
-
The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.Clin Exp Nephrol. 2018 Dec;22(6):1379-1386. doi: 10.1007/s10157-018-1599-6. Epub 2018 Jun 18. Clin Exp Nephrol. 2018. PMID: 29916098
-
Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice.Sci Rep. 2017 Apr 28;7(1):1266. doi: 10.1038/s41598-017-01366-3. Sci Rep. 2017. PMID: 28455534 Free PMC article.
-
Natural Products and Extracts as Xantine Oxidase Inhibitors - A Hope for Gout Disease?Curr Pharm Des. 2021;27(2):143-158. doi: 10.2174/1381612826666200728144605. Curr Pharm Des. 2021. PMID: 32723252 Review.
-
An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.Vasc Health Risk Manag. 2017 Feb 8;13:23-28. doi: 10.2147/VHRM.S115080. eCollection 2017. Vasc Health Risk Manag. 2017. PMID: 28223818 Free PMC article. Review.
Cited by
-
Correlation of retinal nerve fibre layer and macular thickness with serum uric acid among type 2 diabetes mellitus.BMC Ophthalmol. 2017 Jun 14;17(1):91. doi: 10.1186/s12886-017-0486-3. BMC Ophthalmol. 2017. PMID: 28615022 Free PMC article.
-
Basic Science Evidence for the Link Between Erectile Dysfunction and Cardiometabolic Dysfunction.J Sex Med. 2015 Dec;12(12):2233-55. doi: 10.1111/jsm.13069. Epub 2015 Dec 8. J Sex Med. 2015. PMID: 26646025 Free PMC article. Review.
-
Hyperuricemia: A Biomarker of Renal Hemodynamic Impairment.Cardiorenal Med. 2015 Jun;5(3):175-82. doi: 10.1159/000381317. Cardiorenal Med. 2015. PMID: 26195969 Free PMC article. Review.
-
Machine learning algorithm to evaluate risk factors of diabetic foot ulcers and its severity.Med Biol Eng Comput. 2022 Aug;60(8):2349-2357. doi: 10.1007/s11517-022-02617-w. Epub 2022 Jun 25. Med Biol Eng Comput. 2022. PMID: 35751828
-
Can allopurinol improve retinopathy in diabetic rats? Oxidative stress or uric acid; which one is the culprit?Res Pharm Sci. 2017 Oct;12(5):401-408. doi: 10.4103/1735-5362.213985. Res Pharm Sci. 2017. PMID: 28974978 Free PMC article.
References
-
- Pritsos CA. Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. Chem Biol Interact. 2000;129:195–208. - PubMed
-
- Moriwaki Y, Yamamoto T, Suda M, Nasako Y, Takahashi S, Agbedana OE, Hada T, Higashino K. Purification and immunohistochemical tissue localization of human xanthine oxidase. Biochim Biophys Acta. 1993;1164:327–330. - PubMed
-
- Bonomini F, Tengattini S, Fabiano A, Bianchi R, Rezzani R. Atherosclerosis and oxidative stress. Histol Histopathol. 2008;23:381–390. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous